Low omega-6 vs. low omega-6 plus high omega-3 dietary intervention for chronic daily headache: protocol for a randomized clinical trial

Christopher E Ramsden, J Douglas Mann, Keturah R Faurot, Chanee Lynch, Syed Taha Imam, Beth A MacIntosh, Joseph R Hibbeln, James Loewke, Sunyata Smith, Rebecca Coble, Chirayath Suchindran, Susan A Gaylord, Christopher E Ramsden, J Douglas Mann, Keturah R Faurot, Chanee Lynch, Syed Taha Imam, Beth A MacIntosh, Joseph R Hibbeln, James Loewke, Sunyata Smith, Rebecca Coble, Chirayath Suchindran, Susan A Gaylord

Abstract

Background: Targeted analgesic dietary interventions are a promising strategy for alleviating pain and improving quality of life in patients with persistent pain syndromes, such as chronic daily headache (CDH). High intakes of the omega-6 (n-6) polyunsaturated fatty acids (PUFAs), linoleic acid (LA) and arachidonic acid (AA) may promote physical pain by increasing the abundance, and subsequent metabolism, of LA and AA in immune and nervous system tissues. Here we describe methodology for an ongoing randomized clinical trial comparing the metabolic and clinical effects of a low n-6, average n-3 PUFA diet, to the effects of a low n-6 plus high n-3 PUFA diet, in patients with CDH. Our primary aim is to determine if: A) both diets reduce n-6 PUFAs in plasma and erythrocyte lipid pools, compared to baseline; and B) the low n-6 plus high n-3 diet produces a greater decline in n-6 PUFAs, compared to the low n-6 diet alone. Secondary clinical outcomes include headache-specific quality-of-life, and headache frequency and intensity.

Methods: Adults meeting the International Classification of Headache Disorders criteria for CDH are included. After a 6-week baseline phase, participants are randomized to a low n-6 diet, or a low n-6 plus high n-3 diet, for 12 weeks. Foods meeting nutrient intake targets are provided for 2 meals and 2 snacks per day. A research dietitian provides intensive dietary counseling at 2-week intervals. Web-based intervention materials complement dietitian advice. Blood and clinical outcome data are collected every 4 weeks.

Results: Subject recruitment and retention has been excellent; 35 of 40 randomized participants completed the 12-week intervention. Preliminary blinded analysis of composite data from the first 20 participants found significant reductions in erythrocyte n-6 LA, AA and %n-6 in HUFA, and increases in n-3 EPA, DHA and the omega-3 index, indicating adherence.

Trial registration: ClinicalTrials.gov (NCT01157208).

Figures

Figure 1
Figure 1
Study flow diagram for the exploratory analgesic dietary intervention for chronic daily headache, May 2010. Abbreviations: HUFA, highly-unsaturated fatty acid; HIT-6, Headache Impact Test; MIDAS, Migraine Disability Assessment Questionnaire; BSI-18, Brief Symptom Inventory.

References

    1. Scher AI, Stewart WF, Liberman J, Lipton RB. Prevalence of frequent headache in a population sample. Headache. 1998;38(7):497–506. doi: 10.1046/j.1526-4610.1998.3807497.x.
    1. Castillo J, Munoz P, Guitera V, Pascual J. Kaplan Award 1998. Epidemiology of chronic daily headache in the general population. Headache. 1999;39(3):190–196. doi: 10.1046/j.1526-4610.1999.3903190.x.
    1. Stovner L, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, Steiner T, Zwart JA. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007;27(3):193–210. doi: 10.1111/j.1468-2982.2007.01288.x.
    1. Saper JR. Chronic daily headache: transformational migraine, chronic migraine, and related disorders. Current neurology and neuroscience reports. 2008;8(2):100–107. doi: 10.1007/s11910-008-0017-y.
    1. Coeytaux RR, Linville JC. Chronic daily headache in a primary care population: prevalence and headache impact test scores. Headache. 2007;47(1):7–12. doi: 10.1111/j.1526-4610.2007.00647.x.
    1. Nappi G, Perrotta A, Rossi P, Sandrini G. Chronic daily headache. Expert Rev Neurother. 2008;8(3):361–384. doi: 10.1586/14737175.8.3.361.
    1. Dodick DW. Clinical practice. Chronic daily headache. The New England journal of medicine. 2006;354(2):158–165. doi: 10.1056/NEJMcp042897.
    1. Pryse-Phillips W. Assessment and management of disability in chronic daily headache. Current pain and headache reports. 2005;9(1):53–58. doi: 10.1007/s11916-005-0075-7.
    1. Cady R, Farmer K, Dexter JK, Schreiber C. Cosensitization of pain and psychiatric comorbidity in chronic daily headache. Current pain and headache reports. 2005;9(1):47–52. doi: 10.1007/s11916-005-0074-8.
    1. Cady R, Schreiber C, Farmer K, Sheftell F. Primary headaches: a convergence hypothesis. Headache. 2002;42(3):204–216. doi: 10.1046/j.1526-4610.2002.02053.x.
    1. Vonkeman HE, Klok RM, Postma MJ, Brouwers JR, van de Laar MA. Direct medical costs of serious gastrointestinal ulcers among users of NSAIDs. Drugs & aging. 2007;24(8):681–690.
    1. Maizels M. The patient with daily headaches. American family physician. 2004;70(12):2299–2306.
    1. Yurekli VA, Akhan G, Kutluhan S, Uzar E, Koyuncuoglu HR, Gultekin F. The effect of sodium valproate on chronic daily headache and its subgroups. The journal of headache and pain. 2008;9(1):37–41. doi: 10.1007/s10194-008-0002-5.
    1. Park SP, Kwon SH. Cognitive effects of antiepileptic drugs. Journal of clinical neurology (Seoul, Korea) 2008;4(3):99–106. doi: 10.3988/jcn.2008.4.3.99.
    1. Solomon GD. Reducing the cost of headache medication. Current pain and headache reports. 2009;13(3):227–230. doi: 10.1007/s11916-009-0038-5.
    1. Meng ID, Cao L. From migraine to chronic daily headache: the biological basis of headache transformation. Headache. 2007;47(8):1251–1258. doi: 10.1111/j.1526-4610.2007.00907.x.
    1. Richards DA, Bliss TV, Richards CD. Differential modulation of NMDA-induced calcium transients by arachidonic acid and nitric oxide in cultured hippocampal neurons. Eur J Neurosci. 2003;17(11):2323–2328. doi: 10.1046/j.1460-9568.2003.02671.x.
    1. Casado M, Ascher P. Opposite modulation of NMDA receptors by lysophospholipids and arachidonic acid: common features with mechanosensitivity. J Physiol. 1998;513(Pt 2):317–330. doi: 10.1111/j.1469-7793.1998.317bb.x.
    1. Petrenko AB, Yamakura T, Baba H, Shimoji K. The role of N-methyl-D-aspartate (NMDA) receptors in pain: a review. Anesth Analg. 2003;97(4):1108–1116. doi: 10.1213/01.ANE.0000081061.12235.55.
    1. Navarrete M, Araque A. Endocannabinoids mediate neuron-astrocyte communication. Neuron. 2008;57(6):883–893. doi: 10.1016/j.neuron.2008.01.029.
    1. Yang H, Chen C. Cyclooxygenase-2 in synaptic signaling. Current pharmaceutical design. 2008;14(14):1443–1451. doi: 10.2174/138161208784480144.
    1. Yang H, Zhang J, Breyer RM, Chen C. Altered hippocampal long-term synaptic plasticity in mice deficient in the PGE2 EP2 receptor. J Neurochem. 2009;108(1):295–304. doi: 10.1111/j.1471-4159.2008.05766.x.
    1. Grant I, Cahn BR. Cannabis and endocannabinoid modulators: Therapeutic promises and challenges. Clinical neuroscience research. 2005;5(2-4):185–199. doi: 10.1016/j.cnr.2005.08.015.
    1. Wienecke T, Olesen J, Oturai PS, Ashina M. Prostaglandin E2(PGE2) induces headache in healthy subjects. Cephalalgia . 2009. pp. 509–519.
    1. Akerman S, Kaube H, Goadsby PJ. Anandamide acts as a vasodilator of dural blood vessels in vivo by activating TRPV1 receptors. British journal of pharmacology. 2004;142(8):1354–1360. doi: 10.1038/sj.bjp.0705896.
    1. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V, Julius D, Hogestatt ED. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature. 1999;400(6743):452–457. doi: 10.1038/22761.
    1. Peroni RN, Orliac ML, Becu-Villalobos D, Huidobro-Toro JP, Adler-Graschinsky E, Celuch SM. Sex-linked differences in the vasorelaxant effects of anandamide in vascular mesenteric beds: role of oestrogens. European journal of pharmacology. 2004;493(1-3):151–160. doi: 10.1016/j.ejphar.2004.04.031.
    1. Ramsden CE, Gagnon C, Graciosa J, Faurot KR, David R, Brailey JA, Harden RN. Do omega-6 and trans fatty acids play a role in complex regional pain syndrome? A pilot study. Pain medicine (Malden, Mass) 2010. in press .
    1. Li B, Birdwell C, Whelan J. Antithetic relationship of dietary arachidonic acid and eicosapentaenoic acid on eicosanoid production in vivo. J Lipid Res. 1994;35(10):1869–1877.
    1. Salem N Jr, Pawlosky R, Wegher B, Hibbeln J. In vivo conversion of linoleic acid to arachidonic acid in human adults. Prostaglandins, leukotrienes, and essential fatty acids. 1999;60(5-6):407–410. doi: 10.1016/S0952-3278(99)80021-0.
    1. Lands WE, Libelt B, Morris A, Kramer NC, Prewitt TE, Bowen P, Schmeisser D, Davidson MH, Burns JH. Maintenance of lower proportions of (n - 6) eicosanoid precursors in phospholipids of human plasma in response to added dietary (n - 3) fatty acids. Biochim Biophys Acta. 1992;1180(2):147–162.
    1. Xu ZZ, Zhang L, Liu T, Park JY, Berta T, Yang R, Serhan CN, Ji RR. Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nature medicine. pp. 592–597. 591p following 597.
    1. Pocock SJ. Allocation of patients to treatment in clinical trials. Biometrics. 1979;35(1):183–197. doi: 10.2307/2529944.
    1. Mann JD, Faurot KR, Wilkinson L, Curtis P, Coeytaux RR, Suchindran C, Gaylord SA. Craniosacral therapy for migraine: protocol development for an exploratory controlled clinical trial. BMC complementary and alternative medicine. 2008;8:28. doi: 10.1186/1472-6882-8-28.
    1. Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH, Batenhorst A, Cady R, Dahlof CG, Dowson A, Tepper S. A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res. 2003;12(8):963–974. doi: 10.1023/A:1026119331193.
    1. Kawata AK, Coeytaux RR, Devellis RF, Finkel AG, Mann JD, Kahn K. Psychometric properties of the HIT-6 among patients in a headache-specialty practice. Headache. 2005;45(6):638–643. doi: 10.1111/j.1526-4610.2005.05130.x.
    1. Stewart WF, Lipton RB, Kolodner KB, Sawyer J, Lee C, Liberman JN. Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain. 2000;88(1):41–52. doi: 10.1016/S0304-3959(00)00305-5.
    1. Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001;56(6 (Suppl 1)):S20–28.
    1. Lipton RB, Stewart WF, Sawyer J, Edmeads JG. Clinical utility of an instrument assessing migraine disability: the Migraine Disability Assessment (MIDAS) questionnaire. Headache. 2001;41(9):854–861.
    1. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220–233. doi: 10.1097/00005650-199603000-00003.
    1. Luo X, Lynn George M, Kakouras I, Edwards CL, Pietrobon R, Richardson W, Hey L. Reliability, validity, and responsiveness of the short form 12-item survey (SF-12) in patients with back pain. Spine. 2003;28(15):1739–1745.
    1. Lipton RB, Hamelsky SW, Kolodner KB, Steiner TJ, Stewart WF. Migraine, quality of life, and depression: a population-based case-control study. Neurology. 2000;55(5):629–635.
    1. Derogatis LR. BSI-18: Administration, Scoring, and Procedures Manual. Minneapolis, MN: National Computer Systems; 2000.
    1. Derogatis LR, Melisaratos N. The Brief Symptom Inventory: an introductory report. Psychol Med. 1983;13(3):595–605. doi: 10.1017/S0033291700048017.
    1. Borkovec TD, Nau SD. Credibility of analogue therapy rationales. J Behav Therap & Exp Psychiat. 1972;3:257–260.
    1. Devilly GJ, Borkovec TD. Psychometric properties of the credibility/expectancy questionnaire. J Behav Ther Exper Psychiat. 2000;31:73–86. doi: 10.1016/S0005-7916(00)00012-4.
    1. Kalauokalani D, Cherkin DC, Sherman KJ, Koepsell TD, Deyo RA. Lessons from a trial of acupuncture and massage for low back pain: patient expectations and treatment effects. Spine. 2001;26(13):1418–1424. doi: 10.1097/00007632-200107010-00005.
    1. Linde K, Witt CM, Streng A, Weidenhammer W, Wagenpfeil S, Brinkhaus B, Willich SN, Melchart D. The impact of patient expectations on outcomes in four randomized controlled trials of acupuncture in patients with chronic pain. Pain. 2007;128(3):264–271. doi: 10.1016/j.pain.2006.12.006.
    1. Patwardhan AM, Scotland PE, Akopian AN, Hargreaves KM. Activation of TRPV1 in the spinal cord by oxidized linoleic acid metabolites contributes to inflammatory hyperalgesia. Proc Natl Acad Sci USA. 2009;106(44):18820–18824. doi: 10.1073/pnas.0905415106.
    1. Patwardhan AM, Akopian AN, Ruparel NB, Diogenes A, Weintraub ST, Uhlson C, Murphy RC, Hargreaves KM. Heat generates oxidized linoleic acid metabolites that activate TRPV1 and produce pain in rodents. The Journal of clinical investigation. pp. 1617–1626.
    1. Gunthorpe MJ, Chizh BA. Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway. Drug discovery today. 2009;14(1-2):56–67. doi: 10.1016/j.drudis.2008.11.005.
    1. Kingsbury KJ, Paul S, Crossley A, Morgan DM. The fatty acid composition of human depot fat. Biochem J. 1961;78:541–550.
    1. Kingsbury KJ, Heyes TD, Morgan DM, Aylot C, Burton PA, Emmerson R, Robinson PJ. The effect of dietary changes on the fatty acid composition of normal human depot fat. Biochem J. 1962;84:124–133.
    1. Garland M, Sacks FM, Colditz GA, Rimm EB, Sampson LA, Willett WC, Hunter DJ. The relation between dietary intake and adipose tissue composition of selected fatty acids in US women. Am J Clin Nutr. 1998;67(1):25–30.
    1. Blasbalg T, Hibbeln JR, Ramsden CE. Changes in consumption of n-3 and n-6 fatty acids in the 20th century. Bethesda, MD. 2010.
    1. Hodson L, Skeaff CM, Fielding BA. Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake. Prog Lipid Res. 2008;47(5):348–380. doi: 10.1016/j.plipres.2008.03.003.
    1. Katan MB, Deslypere JP, van Birgelen AP, Penders M, Zegwaard M. Kinetics of the incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte membranes, and adipose tissue: an 18-month controlled study. J Lipid Res. 1997;38(10):2012–2022.
    1. Thomas EL, Frost G, Barnard ML, Bryant DJ, Taylor-Robinson SD, Simbrunner J, Coutts GA, Burl M, Bloom SR, Sales KD. et in vivo 13C magnetic resonance spectroscopic study of the relationship between diet and adipose tissue composition. Lipids. 1996;31(2):145–151. doi: 10.1007/BF02522613.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren